Organogenesis price target raised to $7 from $6 at BTIG

BTIG raised the firm’s price target on Organogenesis (ORGO) to $7 from $6 and keeps a Buy rating on the shares after its Q4 results. The firm is also adjusting its model to reflect forward rolled estimates and the company’s recent debt reduction, the analyst tells investors in a research note.